Literature DB >> 837648

Plasma concentrations of 5-(4-hydroxyphenyl)-5-phenylhydantoin in phenytoin-treated patients.

C Hoppel, M Garle, A Rane, F Sjöqvist.   

Abstract

A mass fragmentographic method was used to determine unconjugated and conjugated 5-(4-hydroxyphenyl)-5-phenylhydantonin (4-OH-DPH) in plasma of patients being treated with phenytoin (DPH). The plasma concentration of unconjugated 4-OH-DPH is stable at steady-state for DPH and the level does not change during the dose interval. Most patients (82.5%) have plasma concentrations of unconjugated 4-OH-DPH between 0.04 and 0.2 mug/ml at concentrations of DPH between 5 and 30 mug/ml. Interindividual differences in the ratio between plasma concentration of unconjugated 4-OH-DPH and DPH were noted in a wide range of doses. Dosage adjustments of DPH in patients were not associated with major changes in the plasma level of unconjugated 4-OH-DPH. The plasma concentration of conjugated 4-OH-DPH also showed interindividual differences and varied between 1.2 and 4.5 mug/ml in patients with DPH concentrations between 5 and 30 mug/ml. The data are consistent with the concept of Michaelis-Menten kinetics for DPH metabolism.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 837648     DOI: 10.1002/cpt1977213294

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  6 in total

1.  Rate of phenytoin accumulation in man: a simulation study.

Authors:  T M Ludden; J P Allen; L W Schneider; S A Stavchansky
Journal:  J Pharmacokinet Biopharm       Date:  1978-10

2.  Phenytoin immunoassay measurements in serum samples from patients with renal insufficiency: comparison with high-performance liquid chromatography.

Authors:  Maria J Tutor-Crespo; Jesús Hermida; J Carlos Tutor
Journal:  J Clin Lab Anal       Date:  2007       Impact factor: 2.352

3.  The EMIT FreeLevel ultrafiltration technique compared with equilibrium dialysis and ultracentrifugation to determine protein binding of phenytoin.

Authors:  M Oellerich; H Müller-Vahl
Journal:  Clin Pharmacokinet       Date:  1984-01       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of phenytoin.

Authors:  A Richens
Journal:  Clin Pharmacokinet       Date:  1979 May-Jun       Impact factor: 6.447

Review 5.  Formation of active metabolites of anticonvulsant drugs. A review of their pharmacokinetic and therapeutic significance.

Authors:  M J Eadie
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

6.  Hepatic Bioactivation of Skin-Sensitizing Drugs to Immunogenic Reactive Metabolites.

Authors:  Lor Huai Chong; Celine Ng; Huan Li; Edmund Feng Tian; Abhishek Ananthanarayanan; Michael McMillian; Yi-Chin Toh
Journal:  ACS Omega       Date:  2019-08-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.